Age-Related Behavioral Phenotype of an Astrocytic Monoamine Oxidase-B Transgenic Mouse Model of Parkinson's Disease

被引:50
|
作者
Lieu, Christopher A. [1 ]
Chinta, Shankar J. [1 ]
Rane, Anand [1 ]
Andersen, Julie K. [1 ]
机构
[1] Buck Inst Res Aging, Novato, CA USA
来源
PLOS ONE | 2013年 / 8卷 / 01期
关键词
MAO-B; 3-NITROPROPIONIC ACID; BRAIN ASTROCYTES; KNOCKOUT MICE; PC12; CELLS; MPTP; DEFICIENT; NEURONS; NEUROTOXICITY; DEGENERATION;
D O I
10.1371/journal.pone.0054200
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
We have previously shown that increases in astrocytic monoamine oxidase-B (MAO-B) expression, mimicking that which occurs with aging and in neurodegenerative disease, in a doxycycline (dox)-inducible transgenic mouse model evokes neuropathological similarities to what is observed in the human parkinsonian brain. Additional behavioral and neuropathological studies could provide further validation for its usage as a model for Parkinson's disease (PD). In the present study, we utilized a battery of behavioral tests to evaluate age-related phenotype in this model. In the open field test, we found that dox-induction impaired motor ability with decreases in movement and ambulatory function as well as diminished stereotypical, repetitive movement episodes in both young and old mice. Older mice also showed decreased motor performance in the pole test when compared to younger mice. Furthermore, dox-induced older mice displayed severe hindlimb clasping and the most significant loss of dopamine (DA) in the striatum when compared to young and non-induced animals. Additionally, increased MAO-B activity significantly correlated with decreased expression of striatal DA. The results of our study further confirms that the dox-inducible astrocytic MAO-B transgenic mouse displays similar age-related behavioral and neuropathological features to other models of PD, and could serve as a useful tool to study PD pathophysiology and for the evaluation of therapeutic interventions.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] A polymorphism of monoamine oxidase B and the risk of Parkinson's disease.
    Hernán, MA
    Checkoway, H
    Liu, M
    Costa-Mallen, P
    Kelsey, KT
    Ascherio, A
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2001, 153 (11) : S54 - S54
  • [42] Progressive age-related changes similar to age-related macular degeneration in a transgenic mouse model
    Rakoczy, PE
    Zhang, D
    Robertson, T
    Barnett, NL
    Papadimitriou, J
    Constable, IJ
    Lai, CM
    AMERICAN JOURNAL OF PATHOLOGY, 2002, 161 (04): : 1515 - 1524
  • [43] Age-related irreversible progressive nigrostriatal dopaminergic neurotoxicity in the paraquat and maneb model of the Parkinson's disease phenotype
    Thiruchelvam, M
    McCormack, A
    Richfield, EK
    Baggs, RB
    Tank, AW
    Di Monte, DA
    Cory-Slechta, DA
    EUROPEAN JOURNAL OF NEUROSCIENCE, 2003, 18 (03) : 589 - 600
  • [44] Frailty index and phenotype frailty score: Sex- and age-related differences in 5XFAD transgenic mouse model of Alzheimer's disease
    Todorovic, Smilja
    Loncarevic-Vasiljkovic, Natasa
    Jovic, Milena
    Sokanovic, Srdjan
    Kanazir, Selma
    Djordjevic, Aleksandra Mladenovic
    MECHANISMS OF AGEING AND DEVELOPMENT, 2020, 185
  • [45] Neuroprotective Potential of Polydatin in Combating Parkinson's Disease through the Inhibition of Monoamine Oxidase-B and Catechol-o-Methyl Transferase
    Phukan, Banashree Chetia
    Roy, Rubina
    Choudhury, Shuvasish
    Bhattacharya, Pallab
    Borah, Anupom
    LETTERS IN DRUG DESIGN & DISCOVERY, 2024, 21 (01) : 180 - 188
  • [46] The effect of monoamine oxidase-B inhibitors on the alleviation of depressive symptoms in Parkinson's disease: meta-analysis of randomized controlled trials
    Huang, Yao Hsien
    Chen, Jia Hung
    Loh, El Wui
    Chan, Lung
    Hong, Chien Tai
    THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY, 2021, 11
  • [47] Age-related increases in brain monoamine oxidase B in living healthy human subjects
    Fowler, JS
    Volkow, ND
    Wang, GJ
    Logan, J
    Pappas, N
    Shea, C
    Macgregor, R
    NEUROBIOLOGY OF AGING, 1997, 18 (04) : 431 - 435
  • [48] Characterization of the Monoamine Oxidase-B (MAO-B) Expression in Postmortem Normal and Alzheimer's Disease Brains
    Jaisa-Aad, Methasit
    Connors, Theresa
    Hyman, Bradley
    Serrano-Pozo, Alberto
    NEUROLOGY, 2023, 100 (17)
  • [49] Pharmacokinetics of monoamine oxidase B inhibitors in Parkinson's disease: current status
    Mueller, Thomas
    Moehr, Jan-Dominique
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2019, 15 (05) : 429 - 435
  • [50] Variations in the monoamine oxidase B (MAOB) gene are associated with Parkinson's disease
    Mellick, GD
    Buchanan, DD
    McCann, SJ
    James, KM
    Johnson, AG
    Davis, DR
    Liyou, N
    Chan, D
    Le Couteur, DG
    MOVEMENT DISORDERS, 1999, 14 (02) : 219 - 224